NCT00001662View on ClinicalTrials.gov

Treatment of Alzheimer's Disease With CX516 (Ampalex)

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 1996

Study Completion Date

November 30, 2005

Conditions
Alzheimer's DiseaseDementia
Interventions
DRUG

CX516 (Ampalex)

Trial Locations (1)

20892

National Institute of Neurological Disorders and Stroke (NINDS), Bethesda

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT00001662 - Treatment of Alzheimer's Disease With CX516 (Ampalex) | Biotech Hunter | Biotech Hunter